<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828683</url>
  </required_header>
  <id_info>
    <org_study_id>T120E4</org_study_id>
    <nct_id>NCT02828683</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study</brief_title>
  <acronym>MASTER</acronym>
  <official_title>Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in Management of Patients With Acute ST-Elevation Myocardial InfaRction - MASTER Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo Europe N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terumo Europe N.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to demonstrate the safety and efficacy of the TCD-10023 (Ultimaster)&#xD;
      sirolimus eluting stent in patients with acute ST-elevation myocardial infarction (STEMI), by&#xD;
      proving superiority with respect to in-stent late loss at 6 months to the Kaname bare metal&#xD;
      stent and non-inferiority with respect to Target Vessel Failure (TVF) at 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MASTER is prospective, randomized (3:1), single blind, controlled, superiority (efficacy) and&#xD;
      non-inferiority (safety and efficacy), multi center, two-arm trial of TCD-10023 (Ultimaster)&#xD;
      drug eluting stent (test) and Kaname bare metal stent (comparator).&#xD;
&#xD;
      Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 3&#xD;
      years.&#xD;
&#xD;
      500 patients with clinical follow up will be randomized in 3:1 ratio (375 in TCD-10023 arm&#xD;
      and 125 in Kaname arm). Among them, 100 patients will be randomized in the same, 3:1 ratio,&#xD;
      to angiographic follow up at 6 months in preselected hospitals (75 in TCD-10023 and 25 in&#xD;
      Kaname arm)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite endpoint of cardiac death, target vessel myocardial infarctio and target vessel revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>1 month, 6 months, 12 months, 2 and 3 years</time_frame>
    <description>Composite of cardiac death, target vessel myocardial infarction, target lesion revascularization 2. Target vessel failure (TVF) Comosite of cardiac death, target vessel myocardial infarction, target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>1 month, 6 months, 2 and 3 years</time_frame>
    <description>Composite of cardiac death, target vessel myocardial infarction, target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 month, 6 months, 12 months, 2 and 3 years</time_frame>
    <description>Thrombosis in study stents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient oriented endpoint Composite of any death, any myocardial infarction, any coronary revascularization</measure>
    <time_frame>1 month, 6 months, 12 months, 2 and 3 years</time_frame>
    <description>Composite of any death, any myocardial infarction, any coronary revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>1 month, 6 months, 12 months, 2 and 3 years</time_frame>
    <description>revascularization of treated lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>1 month, 6 months, 12 months, 2 and 3 years</time_frame>
    <description>Access or non access site bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - revascularization, stroke, definite stent thrombosis or major bleeding</measure>
    <time_frame>1 month</time_frame>
    <description>revascularization, stroke, definite stent thrombosis or major bleeding at 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Stent late loss</measure>
    <time_frame>6-mnths</time_frame>
    <description>angiographic assessment of late loss at 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute ST Segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ultimaster, Drug Eluting Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary PCI in patients with ST segment elevation myocardial infarction with a new Drug Eluting Stent, Ultimaster</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kaname, Bare metal stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary PCI in patients with ST segment elevation myocardial infarction with a Bare Metal Stent - Kaname</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCI in patients with ST-elevation myocardial infarction</intervention_name>
    <description>Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)</description>
    <arm_group_label>Ultimaster, Drug Eluting Stent</arm_group_label>
    <other_name>Primary PCI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCI in patients with ST-elevation myocardial infarction</intervention_name>
    <description>Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction</description>
    <arm_group_label>Kaname, Bare metal stent</arm_group_label>
    <other_name>Primary PCI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age equal or more than 18 years&#xD;
&#xD;
          -  Chest pain &gt; 20 minutes&#xD;
&#xD;
          -  Primary PCI &lt;24h from symptoms onset&#xD;
&#xD;
          -  ST-segment elevation of &gt; 1 mm in &gt; 2 contiguous leads, or (presumably new) left&#xD;
             bundle branch block, or true posterior MI with ST depression of &gt; 1 mm in &gt; 2&#xD;
             contiguous anterior leads&#xD;
&#xD;
          -  Presence of at least one acute infarct artery target vessel with one or more coronary&#xD;
             artery stenoses in a native coronary artery from 2.5-4.0 mm in diameter that can be&#xD;
             covered with one or multiple stents&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female of childbearing potential (age &lt; 50 and last menstruation within the last 12&#xD;
             months), who did not underwent tubal ligation, ovariectomy or hysterectomy&#xD;
&#xD;
          -  Known intolerance to aspirin, clopidogrel, heparin, bivalirudin, cobalt, chromium,&#xD;
             nickel, sirolimus or contrast material&#xD;
&#xD;
          -  Currently participating in another trial before reaching primary endpoint&#xD;
&#xD;
          -  Mechanical complication of acute myocardial infarction (e.g. cardiogenic shock…)&#xD;
&#xD;
          -  Acute myocardial infarction secondary to stent thrombosis&#xD;
&#xD;
          -  Previously stented infarction related artery (IRA)&#xD;
&#xD;
          -  Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained&#xD;
             throughout the peri-surgical period&#xD;
&#xD;
          -  Patients with non-cardiac comorbid conditions with life expectancy&lt; 1 year or that may&#xD;
             result in protocol non-compliance&#xD;
&#xD;
          -  History of bleeding diathesis or known coagulopathy&#xD;
&#xD;
          -  Use of oral anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Borovicanin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Terumo Europe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria, Policlinico &quot;Vittorio Emanuele&quot; - Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHE University Cardiology clinic</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zemun (CHC Zemun)</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical center Nis (CCNIs)</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Arrixaca-Murcia</name>
      <address>
        <city>El Palmar</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central Asturias-Oviedo</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DES</keyword>
  <keyword>PCI</keyword>
  <keyword>STEMI</keyword>
  <keyword>Interventional Cardiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

